Literature DB >> 19581879

A detailed characterization of the adult mouse model of glycogen storage disease Ia.

Susan V Salganik1, David A Weinstein, Thomas D Shupe, Max Salganik, Dana G Pintilie, Bryon E Petersen.   

Abstract

Glycogen storage disease type Ia (GSDIa) is caused by a genetic defect in the hepatic enzyme glucose-6-phosphatase (G6Pase-alpha), which manifests as life-threatening hypoglycemia with related metabolic complications. A G6Pase-alpha knockout (KO) mouse model was generated to study potential therapies for correcting this disorder. Since then, gene therapy studies have produced promising results, showing long-term improvement in liver histology and glycogen metabolism. Under existing protocols, however, untreated KO pups seldom survived weaning. Here, we present a thorough characterization of the G6Pase-alpha KO mouse, as well as the husbandry protocol for rearing this strain to adulthood. These mice were raised with only palliative care, and characterized from birth through 6 months of age. Once KO mice have survived the very frail weaning period, their size, agility, serum lipids and glycemic control improve dramatically, reaching levels approaching their wild-type littermates. In addition, our data reveal that adult mice lacking G6Pase-alpha are able to mate and produce viable offspring. However, liver histology and glycogen accumulation do not improve with age. Overall, the reliable production of mature KO mice could provide a critical tool for advancing the GSDIa field, as the availability of a robust enzyme-deficient adult offers a new spectrum of treatment avenues that would not be tolerated by the frail pups. Most importantly, our detailed characterization of the adult KO mouse provides a crucial baseline for accurately gauging the efficacy of experimental therapies in this important model.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19581879      PMCID: PMC3132560          DOI: 10.1038/labinvest.2009.64

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  23 in total

Review 1.  Glycogen storage diseases.

Authors:  Joseph I Wolfsdorf; David A Weinstein
Journal:  Rev Endocr Metab Disord       Date:  2003-03       Impact factor: 6.514

Review 2.  Historical highlights and unsolved problems in glycogen storage disease type 1.

Authors:  Shimon W Moses
Journal:  Eur J Pediatr       Date:  2002-08-23       Impact factor: 3.183

Review 3.  Adenovirus-mediated gene therapy in a mouse model of glycogen storage disease type 1a.

Authors:  Janice Yang Chou; Adriana Zingone; Chi-Jiunn Pan
Journal:  Eur J Pediatr       Date:  2002-07-19       Impact factor: 3.183

4.  A potential new role for muscle in blood glucose homeostasis.

Authors:  Jeng-Jer Shieh; Chi-Jiunn Pan; Brian C Mansfield; Janice Yang Chou
Journal:  J Biol Chem       Date:  2004-04-14       Impact factor: 5.157

5.  A glucose-6-phosphate hydrolase, widely expressed outside the liver, can explain age-dependent resolution of hypoglycemia in glycogen storage disease type Ia.

Authors:  Jeng-Jer Shieh; Chi-Jiunn Pan; Brian C Mansfield; Janice Yang Chou
Journal:  J Biol Chem       Date:  2003-09-16       Impact factor: 5.157

6.  Isolation of the gene for murine glucose-6-phosphatase, the enzyme deficient in glycogen storage disease type 1A.

Authors:  L L Shelly; K J Lei; C J Pan; S F Sakata; S Ruppert; G Schutz; J Y Chou
Journal:  J Biol Chem       Date:  1993-10-15       Impact factor: 5.157

7.  Mutations in the glucose-6-phosphatase gene that cause glycogen storage disease type 1a.

Authors:  K J Lei; L L Shelly; C J Pan; J B Sidbury; J Y Chou
Journal:  Science       Date:  1993-10-22       Impact factor: 47.728

8.  Generation of human artificial chromosomes expressing naturally controlled guanosine triphosphate cyclohydrolase I gene.

Authors:  Masashi Ikeno; Hidehito Inagaki; Keiko Nagata; Miwa Morita; Hiroshi Ichinose; Tuneko Okazaki
Journal:  Genes Cells       Date:  2002-10       Impact factor: 1.891

9.  Mutations in the glucose-6-phosphatase gene are associated with glycogen storage disease types 1a and 1aSP but not 1b and 1c.

Authors:  K J Lei; L L Shelly; B Lin; J B Sidbury; Y T Chen; R C Nordlie; J Y Chou
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

10.  Sustained hepatic and renal glucose-6-phosphatase expression corrects glycogen storage disease type Ia in mice.

Authors:  Mao-Sen Sun; Chi-Jiunn Pan; Jeng-Jer Shieh; Abhijit Ghosh; Li-Yuan Chen; Brian C Mansfield; Jerrold M Ward; Barry J Byrne; Janice Yang Chou
Journal:  Hum Mol Genet       Date:  2002-09-01       Impact factor: 6.150

View more
  5 in total

1.  Neonatal gene therapy of glycogen storage disease type Ia using a feline immunodeficiency virus-based vector.

Authors:  Albert Grinshpun; Reba Condiotti; Simon N Waddington; Michael Peer; Eli Zeig; Sima Peretz; Alina Simerzin; Janice Chou; Chi-Jiunn Pann; Hilla Giladi; Eithan Galun
Journal:  Mol Ther       Date:  2010-06-22       Impact factor: 11.454

Review 2.  Metabolic reprogramming by class I and II histone deacetylases.

Authors:  Maria M Mihaylova; Reuben J Shaw
Journal:  Trends Endocrinol Metab       Date:  2012-10-09       Impact factor: 12.015

Review 3.  Lessons from new mouse models of glycogen storage disease type 1a in relation to the time course and organ specificity of the disease.

Authors:  Fabienne Rajas; Julie Clar; Amandine Gautier-Stein; Gilles Mithieux
Journal:  J Inherit Metab Dis       Date:  2014-08-28       Impact factor: 4.982

4.  Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis.

Authors:  Maria M Mihaylova; Debbie S Vasquez; Kim Ravnskjaer; Pierre-Damien Denechaud; Ruth T Yu; Jacqueline G Alvarez; Michael Downes; Ronald M Evans; Marc Montminy; Reuben J Shaw
Journal:  Cell       Date:  2011-05-13       Impact factor: 41.582

5.  Pathogenesis of Hepatic Tumors following Gene Therapy in Murine and Canine Models of Glycogen Storage Disease.

Authors:  Hye-Ri Kang; Monika Gjorgjieva; Stephanie N Smith; Elizabeth D Brooks; Zelin Chen; Shawn M Burgess; Randy J Chandler; Lauren R Waskowicz; Kylie M Grady; Songtao Li; Gilles Mithieux; Charles P Venditti; Fabienne Rajas; Dwight D Koeberl
Journal:  Mol Ther Methods Clin Dev       Date:  2019-11-11       Impact factor: 6.698

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.